News search

E.g., 17/07/2024
E.g., 17/07/2024
About the CNIC
15 May 2024

Globally, cardiovascular diseases due to atherosclerosis – the build-up of plaque in arteries – are the leading cause of death. A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages and encourage prevention. Denmark’s Novo Nordisk Foundation has granted up to EUR 23 million to cover the first 2.5 years of the REACT initiative. The initiative is expected to run for 8 years in total


RM cardiaca de un paciente con miocardiopatía dilatada (izquierda) y de un individuo sin cardiopatía (derecha). En el paciente con miocardiopatía dilatada el tamaño del corazón esta incrementado y su capacidad de bombeo está disminuida.
Research
19 Apr 2024

The results, published in JACC, suggest that these factors could be used to predict the risk of developing dilated cardiomyopathy and adapt strategies for patient care and disease detection in genetic carriers of the disease

Agustín Clemente-Moragón, Borja Ibáñez, Anabel Díaz-Guerra, Laura Cádiz, Carlos Galán-Arriola, Miguel Fernández-Tocino, Mónica Gómez, Rocío Villena-Gutiérrez, y Eduardo Oliver.
Research
16 Apr 2024

The study, published in the journal JACC: CardioOncology, identifies mitochondrial function and heart metabolism as targets for possible treatments to protect against anthracycline-induced cardiotoxicity

El Dr. Valentín Fuster con la Dra. Guiomar Mendieta
About the CNIC
10 Apr 2024

Guiomar Mendieta has been awarded the 2023 William W. Parmley Young Author Achievement Award for a paper published in JACC that is considered to an outstanding contribution in the field of atherosclerosis

Carlos Torroja, Jacob F. Bentzon, Paula Nogales, Laura Carramolino, Vanessa Cumbicus, Daniel Morales, Ana Dopazo, Verónica Labrador y Alberto Benguria
Research
1 Feb 2024

A study published in Nature Cardiovascular Research reveals smooth muscle-derived cells as a new target for reducing the size of atherosclerotic plaque. The results open up new avenues for the design of treatments to enhance the beneficial effect of cholesterol-lowering drugs


Carla Rothlin
About the CNIC
19 Dec 2023

Dr. Carla Rothlin is Dorys McConnell Duberg Professor of Immunobiology and Professor of Pharmacology at the Yale School of Medicine, and co-leader of the Cancer Immunology Programme at Yale Cancer Centre. She studied biochemistry and pharmacology at the University of Buenos Aires, where she also undertook her postgraduate research under the direction of Dr. Ana Belén Elgoyhen, focussing on nicotinic receptors expressed in the inner ear. Later, she completed her doctorate and moved to San Diego to join Dr. Greg Lemke’s laboratory at the Salk Institute for Biological Studies. In 2009, Dr. Rothlin was named Assistant Professor in Immunobiology at Yale Medical School

Marcos Siguero Álvarez, Luis Luna Zurita, José Luis de la Pompa y Brenda Giselle Flores Garza
Research
11 Dec 2023

The findings, published in the journal Circulation Research, not only highlight the gene regulatory mechanisms that control valve formation, but also offer clues for future medical advances


About the CNIC
17 Nov 2023

This work is of fundamental importance for understanding the immune system and its reactions

The image represent glucose uptake in the brain measured by positron emission tomography in middle-aged individuals with low (top) or high (bottom) sustained cardiovascular risk over 5 years. The colors represent cerebral glucose consumption, with red indicating higher consumption and blue lower consumption
Research
31 Aug 2023

A study published in The Lancet Healthy Longevity shows that brain metabolism, detected with advanced imaging techniques, declines more sharply in middle-aged people with a sustained high cardiovascular risk over 5 years

Rebeca Piñeiro-Sabarís, Marcos Siguero-Álvarez, Donald McGrogan y José Luis de la Pompa.
Research
5 Jul 2023

A multicenter study published in JAMA Cardiology and co-led by scientists at Hadassah Medical Center, Sheba Medical Center, and the CNIC could help in the design of future pharmacological treatments for bicuspid aortic valve